Search Bar & Filters
Found 33 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of sodium zirconium cyclosilicate SZC to help optimize renin-angiotensin aldosterone system inhibitor RAASi therapies in elderly patients aged 70 and older who have heart failure and chronic kidney disease. Many patients with these conditions do not receive recommended RAASi doses because of elevated potassium levels, which can be dangerous. This study aims to see if adding SZC allows safer and more effective use of RAASi medications by managing potassium levels. This is a randomized, open-label clinical trial where eligible participants who have been hospitalized for heart failure worsening and have mild or at-risk hyperkalemia will be assigned to one of two groups. One group receives SZC along with standard RAASi treatment, while the other receives RAASi treatment alone without potassium binders. The treatment period lasts three months, during which RAASi doses are adjusted following European Society of Cardiology guidelines. Participants will be monitored from screening through three months of treatment to measure how many can increase their RAASi doses by at least 25%. Evaluations include clinical assessments, potassium level monitoring, and adherence to therapy. The study will also track secondary outcomes related to higher dose increases. Safety and treatment effects will be observed throughout the trial, which is expected to provide important insights for managing these conditions in elderly patients.
Actively Recruiting
Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to create a registry for patients diagnosed with unresectable locally advanced or metastatic breast cancer, either after recurrence or as a first diagnosis since January 2016. This study aims to understand the distribution of different breast cancer subtypes and patient characteristics over an 8-year period. No specific treatment is assigned by the study, and clinical decisions are made independently by the treating physicians. Participants are grouped based on breast cancer subtypes characterized by receptors such as Estrogen receptor ER, Progesterone receptor PgR, HER2, and Ki-67 expression levels. The study does not intervene in treatment instead, it observes patients receiving standard care as decided by their doctors. Patients may include males and females, and there is no age upper limit. Data collection includes patient and tumor characteristics, biomarker presence in tumor and blood samples, and the impact of surgery timing on patients initially diagnosed with metastatic disease. During the study, participants medical records and disease management data are accessed for analysis. Researchers collect information over 8 years, including subtype distribution, heredofamilial risk, gender differences in disease progression, and biomarker frequency. Patients can withdraw consent at any time, and the treating clinician is encouraged to follow patients until death or study completion. The studys primary outcome is the number of patients with various breast cancer subtypes, with several secondary outcomes related to disease characteristics and treatment timing.
Actively Recruiting
Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are studying chronic primary immune thrombocytopenia ITP, a condition where the immune system mistakenly destroys platelets, leading to easier bruising and bleeding due to low platelet counts. The trial aims to evaluate whether mezagitamab, given as a subcutaneous injection, can maintain stable platelet levels in adults with ITP compared to a placebo. This Phase 3 study is randomized, double-blind, and placebo-controlled to thoroughly assess mezagitamabs effects. Participants will receive either mezagitamab or a matching placebo injection once weekly. The dosing schedule includes 8 weeks of weekly injections, followed by an 8-week break, and then another 8 weeks of weekly injections, totaling up to 6 months of treatment. Those who complete this study or do not respond by week 16 may have the option to join a continuation study to receive open-label mezagitamab if eligible. During the study, participants will visit the clinic multiple times for assessments. Researchers will monitor platelet counts regularly and evaluate responses using measures such as the percentage of participants with durable platelet response up to week 24. Additional assessments include symptom questionnaires, fatigue scores, bleeding events, and monitoring of mezagitamab levels and antibodies. The study also observes safety and treatment effects through week 24 and beyond as needed.
Actively Recruiting
Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.
Actively Recruiting
Researchers are studying post-menopausal women who have been treated for hormone receptor-positive early breast cancer. The study compares the amount of the drug letrozole in the bloodstream after multiple doses of a quarterly injectable form called Letrozole SIE to that after multiple doses of the standard daily oral tablet, Femara4. The goal is to evaluate how the two forms of letrozole compare in steady-state bioavailability, and to understand the elimination phase of Letrozole SIE after repeated doses. The study has four parts a Screening period, Treatment Period 1 TP1, Treatment Period 2 TP2, and an Extension Period. After screening, participants are randomly assigned to receive either US-sourced or EU-sourced oral Femara4 daily for 14 days in TP1 to reach steady-state drug levels. Then, in TP2, all participants receive quarterly injections of Letrozole SIE to achieve steady-state. A subset of about 60 participants will continue into the Extension Period to further assess drug elimination after multiple doses. Participants will undergo breast imaging before baseline and regular assessments including drug concentration measurements, bone mineral density scans, and monitoring for adverse events and injection site reactions. The primary measure is the area under the concentration-time curve at steady state. Safety and other pharmacokinetic parameters will be tracked from consent through the follow-up visits, which may last up to 421 days for some participants. The total study duration includes screening, treatment, and possible extension periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of acalabrutinib combined with the standard chemotherapy regimen R-CHOP for patients with mantle cell lymphoma MCL who have not received prior treatment. This phase II, single-arm, open-label study in Spain aims to understand how well this combination works as a first-line treatment and to monitor patient safety during the process. The study involves approximately 55 participants across multiple centers. Participants will receive acalabrutinib orally twice daily along with up to six 21-day cycles of R-CHOP chemotherapy during the induction phase. After completing six cycles, those who tolerate the treatment and whose disease is not progressing will continue acalabrutinib alone. Participants who respond to treatment will also receive maintenance doses of rituximab every other 28-day cycle for up to 12 doses. Following this maintenance, acalabrutinib monotherapy continues until disease progression or treatment discontinuation. Throughout the study, participants will be regularly assessed with clinical evaluations, including monitoring for response to treatment and safety. The main outcome measured is the best overall response rate approximately one year after starting acalabrutinib. Secondary outcomes include time to response, duration of response, progression-free survival, overall survival, and safety profiles. Participants will be followed from screening until withdrawal, loss to follow-up, death, or study end, with a maximum follow-up of about 30 months after the last participant enrolls.
1-10 of 33
1